JP2004531480A - 神経変性疾患の処置のためのトリペプチド誘導体 - Google Patents

神経変性疾患の処置のためのトリペプチド誘導体 Download PDF

Info

Publication number
JP2004531480A
JP2004531480A JP2002563182A JP2002563182A JP2004531480A JP 2004531480 A JP2004531480 A JP 2004531480A JP 2002563182 A JP2002563182 A JP 2002563182A JP 2002563182 A JP2002563182 A JP 2002563182A JP 2004531480 A JP2004531480 A JP 2004531480A
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
group
amino acid
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002563182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004531480A5 (enExample
Inventor
ラパン，ジャン
ヴィッツマン，ハンス・クラウス
グリュメル，ジャン−マリー
ゴネラ，ジャック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeuroTell AG
Original Assignee
NeuroTell AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NeuroTell AG filed Critical NeuroTell AG
Publication of JP2004531480A publication Critical patent/JP2004531480A/ja
Publication of JP2004531480A5 publication Critical patent/JP2004531480A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2002563182A 2001-02-05 2002-02-05 神経変性疾患の処置のためのトリペプチド誘導体 Withdrawn JP2004531480A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10105039A DE10105039A1 (de) 2001-02-05 2001-02-05 Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
PCT/EP2002/001181 WO2002062830A1 (en) 2001-02-05 2002-02-05 Tripeptide derivatives for the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
JP2004531480A true JP2004531480A (ja) 2004-10-14
JP2004531480A5 JP2004531480A5 (enExample) 2005-12-22

Family

ID=7672832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002563182A Withdrawn JP2004531480A (ja) 2001-02-05 2002-02-05 神経変性疾患の処置のためのトリペプチド誘導体

Country Status (4)

Country Link
EP (1) EP1358204A1 (enExample)
JP (1) JP2004531480A (enExample)
DE (1) DE10105039A1 (enExample)
WO (1) WO2002062830A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523156A (ja) * 2006-01-13 2009-06-18 オンコレー アーベー 癌の処置のためのγ線照射と組み合わせた化合物の使用
JP2016069343A (ja) * 2014-09-30 2016-05-09 森永乳業株式会社 脳機能障害改善剤
JP2018154640A (ja) * 2018-05-17 2018-10-04 森永乳業株式会社 脳機能障害改善用経口組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2622581B1 (fr) * 1987-11-03 1990-02-16 Inorgan Sa Rech Develop Pharm Nouveaux derives de l-proline, leur preparation et leurs applications biologiques
DE4007869A1 (de) * 1990-03-13 1991-09-19 Merck Patent Gmbh Aminosaeurederivate
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
EP0840614A1 (en) * 1995-06-13 1998-05-13 Sanofi Winthrop, Inc. Calpain inhibitors for the treatment of neurodegenerative diseases

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523156A (ja) * 2006-01-13 2009-06-18 オンコレー アーベー 癌の処置のためのγ線照射と組み合わせた化合物の使用
JP2016069343A (ja) * 2014-09-30 2016-05-09 森永乳業株式会社 脳機能障害改善剤
JP2018154640A (ja) * 2018-05-17 2018-10-04 森永乳業株式会社 脳機能障害改善用経口組成物

Also Published As

Publication number Publication date
DE10105039A1 (de) 2002-08-08
EP1358204A1 (en) 2003-11-05
WO2002062830A1 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
JP2002524498A (ja) 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用
US20140323393A1 (en) Uses Of Peptides to Treat Brain Injury and Disease
JP2000514420A (ja) 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ―２５２ａ誘導体の使用
JP2015521608A (ja) 緑内障および他の変性眼疾患のヒトにおける失明の治療のためのインターバル療法
JP2025161811A (ja) タウオパチーを処置するためのペプチド組成物及び方法
JP4169597B2 (ja) 神経変性疾患の処置のためのトリペプチド及びトリペプチド誘導体
WO2023020488A1 (zh) 特拉匹韦在制备治疗缺血/再灌注损伤的药物、细胞保护药物中的应用和方法
EP1420782B1 (en) Use of nefiracetam for treating post-stroke neurodegeneration
JP2004531480A (ja) 神経変性疾患の処置のためのトリペプチド誘導体
US20220257582A1 (en) Treatment for synucleinopathies
US20090068143A1 (en) Orally effective cannabinoid analogs
US20050192228A1 (en) Tripeptide derivatives for the treatment of neurodegenerative diseases
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
US11970521B2 (en) Neuroprotective beta amyloid core peptides and peptidomimetic derivatives
WO2005055997A1 (ja) 炎症性疾患の治療及び予防用医薬組成物
WO2017209027A1 (ja) オートファジー誘導剤
KR101829631B1 (ko) 신규 펩타이드 및 그 용도
KR101943852B1 (ko) 신규 펩타이드 및 그 용도
RS58951B1 (sr) Lečenje multiple skleroze
CN115212194A (zh) 纳多洛尔在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用
JP2002544120A (ja) 逆・反転化プロサポシン由来ポリペプチドおよびその使用
JP2004526701A (ja) 神経系の損傷後疾患の処置のためのトリペプチド誘導体
Spain The melatonin-N, N-dibenzyl (N-methyl) amine hybrid ITH91/IQM157 affords neuroprotection in an in vitro Alzheimers model via Hemo-oxygenase-1 induction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050107

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20051215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051216